Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Tom Drolet who wrote (1662)	4/17/1999 3:24:00 PM
From: DaveAu	Read Replies (2) \| Respond to of 14101

Tom, I don't dispute that the HPB is under-funded. I also don't dispute the possibility/probability that Pennsaid will be approved soon. However I believe that the open study that has seen Pennsaid used by over 3000 patients is a key part. This data wasn't available with the initial submission to HPB and I believe that is why the approval is so long in coming. The data on Celebrex was far more extensive and convincing - that is why they were approved quickly. Celebrex is owned by Monsanto. The Canadian government recently rejected the sale of another Monsanto product (BST) despite it being approved in the US. Maybe the rubber stamp was lost that day. Though you seem to say it facetiously, I do like your idea of "one big UN focused health protection group". The number of drug submissions is increasing very rapidly and its hard for any government to keep up. BJ